NantHealth
NantHealth Q1 Revenues Decline 11 Percent
NantHealth reported a net loss of $15.4 million during the quarter, as sequencing and molecular analysis revenues fell to just $3,000.
NantHealth Lands $137.5M in Financing to Extend Debt Maturity Date
The firm won't have to pay off its unsecured convertible notes until 2026 to investors, including Patrick Soon-Shiong's Nant Capital.
NantHealth Q4 Revenues Flat From Year Ago
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
NantHealth Q3 Revenues Tick Up Slightly
The health IT and precision oncology arm of Patrick Soon-Shiong's NantWorks conglomerate narrowed its quarterly net loss by 32 percent during the quarter.
NantHealth Q2 Revenues Decline 12 Percent
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
May 7, 2020
NantHealth Q1 Revenues Decline 10 Percent
Feb 29, 2020
NantHealth Q4 Revenues Grow 6 Percent
Nov 19, 2019
Nov 12, 2019
FDA Clears NantHealth Tumor-Normal Whole-Exome Test
Nov 7, 2019
NantHealth Q3 Revenues Increase Marginally
Aug 8, 2019
NantHealth Q2 Revenues Grow 17 Percent
May 9, 2019
NantHealth Q1 Revenues Increase 6 Percent
Mar 29, 2019
Mar 28, 2019
NantHealth Q4 Revenues Increase 3 Percent
Jan 18, 2019
NantHealth Receives Nasdaq Delisting Notice
Aug 9, 2018
NantHealth Q2 Revenues Drop 6 Percent
Mar 14, 2018
NantHealth Q4 Revenues Rise 25 Percent
Feb 12, 2018
Nov 9, 2017